Literature DB >> 1659745

Herpes simplex virus: molecular biology and the possibility of corneal latency.

S D Cook1, J H Hill.   

Abstract

Herpes simplex virus (HSV) is known to be latent in ganglionic neurons. Over the past eight years, a series of reports have described the isolation of HSV after organ culture of human corneas that had been removed in the course of penetrating keratoplasty. None of the corneas showed any clinical signs of active herpetic disease immediately before keratoplasty. Studies in rabbits and mice confirmed that HSV can be recovered from corneas by organ culture long after primary infection has subsided. Recently, sophisticated techniques of molecular biology, such as specific DNA or RNA probes, have been used to detect HSV nucleic acids in the cornea. The crux of the matter is whether the virus recovered from or detected in the cornea is 1) truly latent in cell populations that are nonneuronal; 2) resident in the cornea, replicating at a slow rate; or 3) newly arrived in the cornea following ganglionic reactivation. The evidence suggests that a guarded case can be made for limited HSV latency within corneal cells. HSV corneal latency would allow for reactivation, replication, and the immune response to occur in the absence of ganglionic HSV reactivation. Such a localized phenomenon has not, however, been demonstrated to occur clinically.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659745     DOI: 10.1016/0039-6257(91)90127-2

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  16 in total

Review 1.  Herpes simplex virus in the eye.

Authors:  S D Cook
Journal:  Br J Ophthalmol       Date:  1992-06       Impact factor: 4.638

2.  Slow viral replication of HSV-1 is responsible for early recurrence of herpetic keratitis after corneal grafting.

Authors:  J Garweg; M Böhnke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

3.  ["Herpetic keratitis". Various expressions require different therapeutic approaches].

Authors:  B Seitz; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2011-04       Impact factor: 1.059

Review 4.  Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?

Authors:  Lena J Al-Dujaili; Patrick P Clerkin; Christian Clement; Harris E McFerrin; Partha S Bhattacharjee; Emily D Varnell; Herbert E Kaufman; James M Hill
Journal:  Future Microbiol       Date:  2011-08       Impact factor: 3.165

5.  Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy.

Authors:  P A Asbell
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 6.  Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts.

Authors:  Uday K Bhatt; M N Abdul Karim; Jeremy I Prydal; Senthil V Maharajan; Usama Fares
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

7.  Tracking the spread of a lacZ-tagged herpes simplex virus type 1 between the eye and the nervous system of the mouse: comparison of primary and recurrent infection.

Authors:  C Shimeld; S Efstathiou; T Hill
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

8.  HSV-1 antigens and DNA in the corneal explant buttons of patients with non-herpetic or clinically atypical herpetic stromal keratitis.

Authors:  Justus Gerhard Garweg; Christiane Elisabeth Russ; Marc Schellhorn; Matthias Böhnke; Markus Halberstadt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-06-21       Impact factor: 3.117

Review 9.  Epigenetic regulation of latent HSV-1 gene expression.

Authors:  David C Bloom; Nicole V Giordani; Dacia L Kwiatkowski
Journal:  Biochim Biophys Acta       Date:  2010-01-04

10.  Detection of herpes simplex virus DNA in donor cornea culture medium by polymerase chain reaction.

Authors:  D J Morris; G M Cleator; P E Klapper; R J Cooper; E O Biney; C Dennett; B Marcyniuk; A B Tullo
Journal:  Br J Ophthalmol       Date:  1996-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.